AACR: HER2 targeted therapy shows promise in previously treated lung cancers
Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer.Â
These cancers are associated with resistance to standard therapies and a very poor prognosis. As an oral pill, zongertinib would be a more convenient option for patients.  Trial data prompted a priority review by the Food and Drug Administration (FDA) earlier this year and sparked a...
These cancers are associated with resistance to standard therapies and a very poor prognosis. As an oral pill, zongertinib would be a more convenient option for patients.  Trial data prompted a priority review by the Food and Drug Administration (FDA) earlier this year and sparked a...
MD Anderson researchers develop novel antibody-toxin conjugate
Researchers at Â鶹ӳ» MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to stimulate...
MD Anderson, the Oden Institute and TACC announce funding for six new collaborative cancer projects
Â鶹ӳ» MD Anderson Cancer Center, the Oden Institute for Computational Engineering and Sciences and the Texas Advanced Computing...
Funda Meric-Bernstam, M.D., elected to National Academy of Medicine
Funda Meric-Bernstam, M.D., chair of Investigational Cancer Therapeutics at Â鶹ӳ» MD Anderson Cancer Center, has been elected to the National Academy of Medicine (NAM) for her contributions to precision oncology, therapeutics development and biomarker discovery, and for leading practice-changing clinical trials.
The NAM, originally established as the Institute of Medicine in 1970 by the National Academy of Sciences...
MD Anderson Research Highlights Special Edition: ASTRO 2024
Â鶹ӳ» MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Allison Institute and Institute for Data Science in Oncology blend spatial biology efforts by appointing new member
The James P. Allison Instituteâ„¢ and the Institute for Data Science in Oncology  (IDSO) at Â鶹ӳ» MD Anderson Cancer...
ESMO: Novel ADC AZD8205 demonstrates manageable safety profile and preliminary efficacy in first-in-human trial
ABSTRACT: 606O
BARCELONA, Spain – The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety...
MD Anderson and Rice launch initiative to advance cancer-focused operations research
Â鶹ӳ» MD Anderson Cancer Center and Rice University today announced the launch of the Center for Operations Research in...
Study supports precision radiation therapy in lung cancer
Results from a new study led by researchers at Â鶹ӳ» MD Anderson Cancer Center support standard use of the more precise...
MD Anderson’s Institute for Data Science in Oncology establishes internal advisory council to maximize impact
The Institute for Data Science in Oncology (IDSO) at Â鶹ӳ»â€¯MD Anderson Cancer Center today announced the establishment of...